What is CytoTronics?
CytoTronics specializes in advanced Pixel systems engineered for cell biology discovery, enabling researchers to visualize live cell functions at an unprecedented scale. Their technology facilitates multiplexed live-cell readouts, capturing extensive data on cell viability, morphology, and electrophysiology across various cell models. The company targets scientists in therapeutic areas such as vascular biology, stem cell differentiation, and oncology, empowering cell biologists to unlock new applications and insights. CytoTronics' cloud-based software aids in the rapid analysis of rich data, enhancing the understanding of cellular behavior.
How much funding has CytoTronics raised?
CytoTronics has raised a total of $22.8M across 2 funding rounds:
Angel/Seed
$9.3M
Angel/Seed
$13.5M
Angel/Seed (2022): $9.3M with participation from Anzu Partners and Milad Alucozai
Angel/Seed (2024): $13.5M led by BoxOne Ventures, LYFE Capital, Draper Associates, and Anzu Partners
Key Investors in CytoTronics
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets. They provide expertise in business development and market positioning to accelerate growth.
BoxOne Ventures
BoxOne Ventures is a privately held investment firm that specializes in early-stage companies within impactful sectors such as biotechnology and longevity, investing their own capital to support entrepreneurs from inception to IPO.
LYFE Capital
LYFE Capital is a premier healthcare investment platform focusing on critical healthcare supply chain assets and next-generation R&D services, aiming to generate significant revenues from mature global markets.
What's next for CytoTronics?
The substantial enterprise-level funding positions CytoTronics for significant scaling and further development of its advanced Pixel systems. This strategic investment is expected to accelerate market penetration and enhance research and development capabilities, particularly in areas like therapeutic discovery and cellular analysis. The company's focus on enabling deeper insights into cell biology suggests a trajectory towards becoming a key player in the life sciences and biotechnology sectors, potentially driving innovation in drug development and disease research.
See full CytoTronics company page
